Skyrizi Global Market Opportunities And Strategies To 2035

Skyrizi Market Definition

Skyrizi (risankizumab) refers to a prescription biologic medication developed and commercialized by AbbVie Inc., belonging to the class of interleukin-23 (IL-23) inhibitors. It is specifically designed to selectively block the IL-23 cytokine, a key driver of chronic inflammatory responses, thereby reducing inflammation and associated tissue damage in patients with immune-mediated inflammatory diseases. Skyrizi is available in two formulations, pre-filled syringes for subcutaneous administration and intravenous (IV) infusion vials for certain indications, offering flexible delivery options depending on the disease condition and treatment setting. The skyrizi market consists of revenues generated from the sale of risankizumab-rzaa (Skyrizi) by AbbVie Inc. across its approved therapeutic indications, including moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving patients across all major global regions including North America, Western Europe, Asia-Pacific, Eastern Europe, South America, the Middle East, and Africa.

Skyrizi Market Segmentation

The skyrizi market is segmented by indication, by formulation and by distribution channel.

By Indication –
The skyrizi market is segmented by indication into:

• a) Psoriatic Disease
• b) Crohn's Disease
• c) Ulcerative Colitis

The psoriatic disease market was the largest segment of the skyrizi market segmented by indication, accounting for 69.5% or $9,714.6 million of the total in 2025. Going forward, the crohn's disease segment is expected to be the fastest growing segment in the skyrizi market segmented by indication, at a CAGR of 19.4% during 2025-2030.

By Formulation –
The skyrizi market is segmented by formulation into:

• a) Pre-Filled Syringes
• b) Vials

The pre-filled syringes market was the largest segment of the skyrizi market segmented by formulation, accounting for 69.5% or $9,714.6 million of the total in 2025. Going forward, the vials segment is expected to be the fastest growing segment in the skyrizi market segmented by formulation, at a CAGR of 18.6% during 2025-2030.

By Distribution Channel –
The skyrizi market is segmented by distribution channel into:

• a) Hospital Pharmacies
• b) Retail Pharmacies
• c) Online Pharmacies

The hospital pharmacies market was the largest segment of the skyrizi market segmented by distribution channel, accounting for 49.2% or $6,880.5 million of the total in 2025. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the skyrizi market segmented by distribution channel, at a CAGR of 20.0% during 2025-2030.

By Geography - The skyrizi market is segmented by geography into:

o Asia Pacific
• • China
• • India
• • Japan
• • Australia
• • Indonesia
• • South Korea
o North America
• • USA
• • Canada
o South America
• • Brazil
o Western Europe
• • France
• • Germany
• • UK
• • Italy
• • Spain
o Eastern Europe
• • Russia
o Middle East
o Africa

North America was the largest region in the skyrizi market, accounting for 85.0% or $11,889.0 million of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the skyrizi market will be Asia Pacific and Middle East where growth will be at CAGRs of 43.4% and 43.2% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 35.2% and 30.4% respectively.

Skyrizi Market Drivers

The key drivers of the skyrizi market include: Rising Prevalence Of Chronic Diseases The rising prevalence of chronic diseases is anticipated to drive the growth of the skyrizi market in the coming years. Skyrizi plays an important role in the management of chronic immune-mediated inflammatory conditions by selectively targeting the IL-23 cytokine pathway, thereby reducing inflammation and enabling durable disease control in conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As the global burden of chronic diseases continues to increase, the demand for advanced biologic therapies capable of delivering sustained remission and improved quality of life is expected to grow. Consequently, the rising prevalence of chronic diseases is expected to fuel demand for skyrizi across all approved indications.

Skyrizi Market Restraints

The key restraints on the skyrizi market include: Strict Regulatory And Prescribing Guidelines Strict regulatory and prescribing guidelines are restricting the growth of the skyrizi market during the forecast period. Complex and variable prior authorization requirements, utilization management policies, and prescribing constraints for biologic therapies can lead to administrative burdens, delayed treatment initiation, and inconsistent access across healthcare settings. These administrative hurdles often result in discontinuities in therapy, increased healthcare provider workload, and hesitation among clinicians to prescribe certain advanced therapies due to uncertainty in reimbursement pathways.

Skyrizi Market Competitive Landscape

Major Competitors are:

AbbVie Inc.

Other Competitors Include:

AbbVie Inc.

Eisai Co. Ltd.

Daiichi Sankyo

UCB S.A.

Novartis AG

Amgen Inc.

Bristol-Myers Squibb

Skyrizi Market Trends

Major trends shaping the skyrizi market include: Expansion Of Indication Approvals For Advanced Biologic Therapies Major companies operating in the skyrizi market are focusing on the expansion of indication approvals for advanced biologic therapies to address the growing unmet medical need across immune-mediated inflammatory diseases. These strategies aim to broaden the patient population eligible for treatment with targeted IL-23 inhibitors, support continued revenue growth, and strengthen competitive positioning against alternative biologics. For instance, AbbVie continues to pursue regulatory approvals across new indications and geographies for risankizumab, reinforcing its market leadership in the biopharmaceutical space. Expanding Regulatory Approvals For IL-23 Inhibitors Major companies operating in the skyrizi market are focusing on expanding regulatory approvals for IL-23 inhibitors across additional therapeutic indications and global markets. These efforts reflect growing clinical confidence in the safety and efficacy of the IL-23 inhibitor class and increasing recognition by regulatory authorities of the therapeutic benefits for patients with chronic inflammatory conditions. The expanding regulatory landscape for IL-23 inhibitors is expected to unlock new patient segments and markets, contributing to sustained market growth throughout the forecast period.

Opportunities And Recommendations In The Skyrizi Market

Opportunities – The top opportunities in the skyrizi markets segmented by indication will arise in the psoriatic disease segment, which will gain $11,014.9 million of global annual sales by 2030. The top opportunities in the skyrizi markets segmented by formulation will arise in the pre-filled syringes segment, which will gain $11,014.9 million of global annual sales by 2030. The top opportunities in the skyrizi markets segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $7,565.2 million of global annual sales by 2030. The skyrizi market size will gain the most in the USA at $11,039.7 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the skyrizi companies to focus on expanding multi indication approvals for skyrizi, focus on expanding regulatory approvals for IL 23 inhibitors, focus on crohn’s disease for accelerated growth, focus on expanding vial-based delivery for clinical settings, expand in emerging markets, continue to focus on developed markets, focus on value based and flexible pricing strategies, focus on expanding online pharmacy distribution channels and focus on strengthening stakeholder engagement and clinical expertise.